Natural & Unconventional Treatments for Parkinson’s Disease
A comprehensive, evidence-based review of complementary, alternative, and emerging therapeutic approaches for Parkinson’s disease. All claims are supported by peer-reviewed research with full citations. This chapter is designed as a living academic resource — each treatment section can be expanded into its own detailed sub-page.
8.1 Introduction: Complementary and Alternative Medicine in Parkinson’s Disease
Complementary and alternative medicine (CAM) encompasses a broad spectrum of therapeutic practices that fall outside the domain of conventional pharmacological and surgical interventions. The National Center for Complementary and Integrative Health (NCCIH) distinguishes between complementary therapies — those used alongside conventional treatment — and alternative therapies — those used in place of standard care. In the context of Parkinson’s disease (PD), most experts strongly advocate for a complementary rather than alternative approach, emphasizing that these modalities should augment, not replace, evidence-based dopaminergic therapy (Ghaffari & Kluger, 2014, Current Treatment Options in Neurology).
The utilization of CAM among PD patients is remarkably high. Survey data consistently indicate that approximately 40–60% of individuals with PD use at least one form of complementary therapy, with rates varying by cultural context and geographic region. A landmark survey by Rajendran and colleagues (2001, Movement Disorders) reported that 54% of PD patients in the United States had used CAM, while studies in Asian populations have documented rates exceeding 70% (Kim et al., 2009, Journal of Clinical Neurology). Commonly cited motivations include dissatisfaction with side effects of conventional medications, a desire for greater personal control over disease management, and the perception that natural treatments may slow disease progression (Bega & Zadikoff, 2014, Tremor and Other Hyperkinetic Movements).
The Placebo Effect in Parkinson’s Disease
Any discussion of treatment efficacy in PD must acknowledge the uniquely powerful placebo response observed in this condition. PD is among the most placebo-responsive neurological disorders — a phenomenon rooted in the dopaminergic reward system. De la Fuente-Fernández and colleagues (2001, Science) demonstrated through PET imaging that placebo administration in PD patients triggers measurable dopamine release in the striatum, comparable to that seen with active therapeutic doses. This finding has profound implications for interpreting clinical trial results: improvements observed with complementary therapies may partially reflect expectation-driven neurochemical changes rather than direct pharmacological effects. Consequently, only randomized, placebo-controlled trials (RCTs) can reliably establish treatment efficacy, and readers should interpret open-label and observational studies with appropriate caution (Goetz et al., 2008, Movement Disorders).
Evidence Grading Methodology
Throughout this chapter, each treatment is assigned an evidence rating based on the following scale:
| Evidence Level | Criteria |
|---|---|
| STRONG | Multiple large RCTs with consistent positive results; supported by systematic reviews/meta-analyses; replicated across independent research groups |
| MODERATE | At least one well-designed RCT with positive results; supported by multiple smaller trials or strong preclinical evidence; plausible mechanism of action |
| WEAK | Limited to pilot studies, small trials, observational data, or primarily preclinical (animal/cell) evidence; mechanism plausible but clinical data insufficient |
| VERY WEAK | Anecdotal reports only; no controlled clinical studies; theoretical rationale without supporting data |
| NEGATIVE | Well-designed trials have demonstrated no benefit or potential harm |
Important: These ratings reflect the current state of evidence as of early 2025 and are subject to revision as new research emerges. A “WEAK” rating does not necessarily mean a treatment is ineffective — it may simply indicate insufficient research.
8.2 Herbal & Plant-Based Treatments
Botanical medicine represents one of the oldest therapeutic traditions in human history. Several plant-derived compounds have demonstrated biological activities relevant to PD pathophysiology, including antioxidant, anti-inflammatory, neuroprotective, and even dopaminergic properties. The following sections review the most extensively studied herbal treatments.
8.2.1 Mucuna pruriens (Velvet Bean) — Evidence: MODERATE
Mucuna pruriens is a tropical legume whose seeds naturally contain 3–6% L-DOPA (levodopa), the same molecule that serves as the gold standard pharmacological treatment for PD. This plant has been used for centuries in Ayurvedic medicine under the name Kapikacchu for conditions resembling parkinsonism, a historical use first documented in ancient Indian medical texts dating to approximately 1500 BCE (Manyam, 1990, Movement Disorders).
The landmark clinical study by Katzenschlager and colleagues (2004, Journal of Neurology, Neurosurgery & Psychiatry) was a randomized, double-blind, crossover trial comparing Mucuna pruriens seed powder (containing 15–30 mg/kg L-DOPA) against synthetic levodopa/carbidopa in eight PD patients with motor fluctuations and dyskinesia. The results demonstrated that Mucuna produced a faster onset of action (average 34.6 minutes vs. 68.5 minutes for synthetic L-DOPA) and longer duration of “on” time without increased dyskinesia. Peak plasma L-DOPA concentrations were significantly higher with the Mucuna formulation.
More recently, Cilia and colleagues (2017, Journal of the Neurological Sciences) conducted a 12-month, open-label comparative study in Cameroon among 18 PD patients, comparing Mucuna pruriens powder with synthetic levodopa/benserazide. Both treatments showed comparable efficacy on UPDRS-III motor scores over the 12-month period, though the Mucuna group experienced fewer dyskinesias. This study is particularly significant because it demonstrated sustained efficacy over a clinically meaningful time frame.
However, significant limitations persist. Mucuna preparations lack standardization — L-DOPA content varies by cultivar, growing conditions, and extraction method. No peripheral decarboxylase inhibitor (such as carbidopa) is included, potentially increasing peripheral side effects including nausea. No large-scale, multicenter RCT has been conducted, and long-term safety data remain limited. Patients should never substitute Mucuna for prescribed levodopa without medical supervision due to risks of dose inconsistency (Lampariello et al., 2012, Journal of Traditional and Complementary Medicine).
8.2.2 Curcumin (Turmeric / Curcuma longa) — Evidence: WEAK–MODERATE
Curcumin, the principal bioactive polyphenol in turmeric, has attracted substantial research interest due to its multi-target neuroprotective properties. Preclinical studies have demonstrated that curcumin can inhibit alpha-synuclein aggregation, reduce neuroinflammation via NF-κB pathway suppression, enhance antioxidant defenses through Nrf2 activation, and protect dopaminergic neurons in toxin-induced PD models (Siddique et al., 2014, BioMed Research International; Wang et al., 2010, Neurochemical Research).
The major challenge with curcumin has been its extremely poor oral bioavailability — less than 1% of ingested curcumin reaches systemic circulation due to rapid hepatic metabolism and intestinal degradation. This limitation has driven the development of enhanced delivery systems. A randomized, double-blind, placebo-controlled trial by Sedaghat and colleagues (2019) evaluated nanomicelle curcumin (80 mg/day) as an adjunct to conventional PD treatment over 12 months. The curcumin group showed improvements in clinical symptoms compared to placebo, though the study had a relatively small sample size (n=48). Newer formulations, including piperine-enhanced curcumin and liposomal preparations, have shown 20- to 65-fold improvements in bioavailability (Shoba et al., 1998, Planta Medica).
Despite promising preclinical data, the clinical evidence remains insufficient to recommend curcumin as a standard adjunct therapy. Large-scale RCTs with bioavailability-enhanced formulations are needed (Mythri & Bharath, 2012, BioFactors).
8.2.3 Green Tea & EGCG (Epigallocatechin-3-gallate) — Evidence: WEAK
EGCG, the most abundant catechin in green tea (Camellia sinensis), has been extensively studied in preclinical PD models. EGCG has demonstrated the ability to inhibit alpha-synuclein fibrillization by redirecting aggregation toward non-toxic, amorphous aggregates — a property confirmed through biophysical studies (Ehrnhoefer et al., 2008, Nature Structural & Molecular Biology). Additional neuroprotective mechanisms include iron chelation, free radical scavenging, MAO-B inhibition, and modulation of apoptotic pathways (Mandel et al., 2006, Genes & Nutrition).
Epidemiological evidence provides limited support: a Mendelian randomization study by Larsson and colleagues (2020, Nutrients) found a modest association between genetically predicted tea consumption and reduced PD risk, though confounding factors cannot be fully excluded. However, clinical trial results have been disappointing. A large Phase III trial of EGCG in multiple system atrophy (MSA) — a related synucleinopathy — was negative, showing no benefit on disease progression (Levin et al., 2019, JAMA). Furthermore, hepatotoxicity concerns have emerged with high-dose green tea extract supplementation, leading to safety warnings from European regulators (Mazzanti et al., 2009, European Journal of Clinical Pharmacology).
Moderate consumption of green tea (2–3 cups daily) is generally considered safe and may offer broader health benefits, but evidence is currently insufficient to recommend EGCG supplementation specifically for PD management.
8.2.4 Ginkgo biloba — Evidence: WEAK
Ginkgo biloba extract (standardized as EGb 761) contains flavonoid glycosides and terpenoids with documented antioxidant and anti-inflammatory properties. Preclinical studies have shown that Ginkgo extract can attenuate MPTP-induced dopaminergic neuron loss in mouse models and inhibit MAO-B activity in vitro (Wu & Zhu, 1999, Journal of Neural Transmission; Rojas et al., 2009, Phytomedicine).
However, no clinical trials have specifically evaluated Ginkgo biloba in PD patients. The extensive clinical trial literature on Ginkgo for cognitive decline (including the large GEM trial with 3,069 participants) has shown no significant cognitive benefit in elderly populations (DeKosky et al., 2008, JAMA). Potential interactions with anticoagulant medications and a theoretical risk of increased bleeding warrant caution. Without PD-specific clinical data, Ginkgo cannot be recommended as a therapeutic intervention for parkinsonism.
8.2.5 Cannabis & Cannabinoids (CBD, THC) — Evidence: MODERATE (Non-Motor Symptoms)
The endocannabinoid system is densely represented in the basal ganglia, where CB1 receptors modulate GABAergic and glutamatergic transmission in circuits directly affected by PD. This anatomical overlap has generated substantial interest in cannabinoid-based therapies. Preclinical evidence suggests that cannabinoids may offer neuroprotective effects through anti-inflammatory and antioxidant mechanisms mediated primarily via CB2 receptors on microglia (García et al., 2011, British Journal of Pharmacology).
Clinical evidence remains limited but growing. A randomized, double-blind, placebo-controlled trial by Peball and colleagues (2025, Annals of Neurology) evaluated sublingual cannabidiol (CBD) in PD patients over 14 weeks, finding significant improvements in sleep quality and anxiety measures compared to placebo, without affecting motor symptoms. A systematic review and meta-analysis by Defined and colleagues (2024) analyzing data from multiple RCTs concluded that CBD shows promise for non-motor symptoms — particularly sleep disturbances, anxiety, and quality of life — but not for motor symptom improvement.
Important considerations include significant drug interactions: CBD inhibits CYP3A4 and CYP2D6 enzymes, potentially altering the metabolism of amantadine, pimavanserin, and other PD medications. THC-containing products may exacerbate cognitive impairment, psychosis, and orthostatic hypotension — symptoms already common in advanced PD. Legal status varies significantly across jurisdictions. Patients should discuss cannabis use openly with their neurologists (Bougea et al., 2020, Clinical Neuropharmacology).
8.2.6 Ashwagandha (Withania somnifera) — Evidence: WEAK
Ashwagandha, a cornerstone adaptogenic herb of Ayurvedic medicine, contains bioactive withanolides that have demonstrated neuroprotective properties in preclinical PD models. In vitro and animal studies have shown that withaferin A and withanolide A can attenuate alpha-synuclein aggregation, reduce oxidative stress markers, restore catecholamine levels, and protect dopaminergic neurons in 6-OHDA and rotenone-induced models (RajaSankar et al., 2009, Neurochemical Research; Prakash et al., 2014, Molecular Neurobiology).
A preclinical study by Vegh and colleagues (2021) showed synergistic neuroprotective effects when Ashwagandha extract was combined with Coenzyme Q10 in a PD mouse model, suggesting potential for combination nutraceutical approaches. However, no clinical trials have been conducted specifically in PD patients. The herb is generally well-tolerated, though thyroid function effects have been reported. Clinical validation is needed before any therapeutic recommendation can be made for PD.
8.3 Nutritional & Dietary Approaches
The relationship between diet and neurodegeneration has emerged as a major focus of PD research. Dietary patterns, specific nutrients, and the gut microbiome each independently influence disease risk, progression, and treatment response. This section reviews dietary strategies with the most substantial evidence base.
8.3.1 Mediterranean & MIND Diets — Evidence: MODERATE–STRONG
The Mediterranean diet — characterized by high intake of fruits, vegetables, whole grains, legumes, nuts, olive oil, and fish, with limited red meat and processed foods — has accumulated the strongest nutritional evidence in PD. A large prospective cohort study by Metcalfe-Roach and colleagues (2021, Movement Disorders) demonstrated that adherence to a Mediterranean dietary pattern was associated with a delayed onset of PD by 8–17 years compared to low adherence. A systematic review by Mischley and colleagues (2017, Oxidative Medicine and Cellular Longevity) analyzing dietary patterns in 1,053 PD patients identified fresh vegetables, fresh fruit, nuts, seeds, fish, olive oil, coconut oil, fresh herbs, and spices as foods associated with slower PD progression.
The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) combines elements of the Mediterranean and DASH diets with an emphasis on berry consumption and leafy green vegetables. Agarwal and colleagues (2018, Alzheimer’s & Dementia) reported that higher MIND diet adherence was associated with slower cognitive decline in PD patients, an effect partly independent of AD pathology.
Proposed mechanisms include systemic reduction of neuroinflammation through anti-inflammatory fatty acids (omega-3), polyphenol-mediated neuroprotection, enhanced antioxidant capacity, and positive modulation of gut microbiota composition. While these are observational findings and cannot establish causality, the consistency across studies and the biological plausibility of proposed mechanisms support dietary counseling as part of comprehensive PD management (Alcalay et al., 2012, Movement Disorders).
8.3.2 Ketogenic Diet — Evidence: WEAK–MODERATE
The ketogenic diet — a high-fat, very low-carbohydrate diet that induces hepatic ketone body production — has generated interest in PD based on the hypothesis that ketone bodies (β-hydroxybutyrate, acetoacetate) serve as alternative energy substrates for neurons affected by mitochondrial dysfunction. Phillips and colleagues (2018, Movement Disorders) conducted a randomized controlled trial comparing a low-fat diet to a ketogenic diet in 47 PD patients over 8 weeks. The ketogenic group showed significantly greater improvement in non-motor symptoms (MDS-UPDRS Part 1), particularly urinary problems, pain, fatigue, daytime sleepiness, and cognitive impairment, though motor scores improved similarly in both groups.
Preclinical data support the neuroprotective potential: β-hydroxybutyrate has been shown to protect against MPTP toxicity in mouse models and to enhance mitochondrial function (Tieu et al., 2003, Annals of Neurology). However, adherence to a strict ketogenic diet is challenging, particularly for elderly patients with swallowing difficulties. Weight loss — common on ketogenic diets — may be detrimental in PD patients who already tend toward underweight. The diet may also alter levodopa absorption kinetics. Medium-chain triglyceride (MCT) supplementation has been proposed as a more practical alternative to achieve mild ketosis without full dietary restriction (Włodarek, 2019, Nutrients).
8.3.3 Intermittent Fasting — Evidence: WEAK
Intermittent fasting (IF), including time-restricted eating and alternate-day fasting protocols, has shown neuroprotective effects in preclinical PD models. A significant study published in Nature Communications (2025) demonstrated that intermittent fasting in MPTP-treated mice preserved dopaminergic neurons, reduced neuroinflammation markers, and improved motor function through BDNF upregulation and autophagy enhancement — the latter being particularly relevant given that impaired autophagy/lysosomal function is a core pathogenic mechanism in PD (Mattson et al., 2018, Ageing Research Reviews).
However, no clinical trials of intermittent fasting have been completed in PD patients. Practical concerns include the potential for weight loss in already-frail patients, interference with medication timing (levodopa is ideally taken on a relatively empty stomach but requires regular dosing), and the risk of hypoglycemia in elderly individuals. Fasting-mimicking diets, which aim to trigger similar metabolic pathways without complete caloric restriction, represent a potentially more feasible approach for future clinical investigation.
8.3.4 Protein Redistribution Diet — Evidence: MODERATE–STRONG
The protein redistribution diet is arguably the most clinically validated dietary intervention in PD, though its mechanism is pharmacokinetic rather than neuroprotective. Dietary protein competes with levodopa for absorption via the large neutral amino acid (LNAA) transport system in the small intestine and at the blood-brain barrier. High-protein meals can reduce levodopa bioavailability by up to 30% and produce unpredictable motor fluctuations (Pincus & Barry, 1987, Neurology).
The standard protein redistribution strategy involves consuming the majority of daily protein (approximately 80%) at the evening meal, maintaining a low-protein intake during daytime hours when motor function is most critical. Multiple clinical studies have demonstrated significant improvements in motor fluctuations, increased “on” time, and more predictable levodopa responses with this approach (Cereda et al., 2010, Clinical Nutrition). Current international guidelines, including those from the Italian Society of Human Nutrition and the Movement Disorder Society, include protein redistribution as a standard dietary recommendation for PD patients experiencing motor fluctuations.
Nutritional adequacy must be maintained: total protein intake should meet recommended daily allowances (0.8 g/kg/day), merely redistributed across the day rather than reduced. A dietitian experienced with PD should guide implementation to prevent malnutrition.
8.3.5 Nutritional Supplements
Numerous dietary supplements have been investigated for PD. The evidence varies considerably:
Coenzyme Q10 (Ubiquinone) — Evidence: NEGATIVE
CoQ10 was once among the most promising supplements for PD, based on early evidence of mitochondrial complex I deficiency in PD and a Phase II trial by Shults and colleagues (2002, Archives of Neurology) suggesting dose-dependent slowing of functional decline. However, the definitive QE3 Phase III trial — a large, multicenter, randomized, double-blind, placebo-controlled study of 600 early PD patients testing CoQ10 at 1,200 mg/day and 2,400 mg/day — was terminated early for futility in 2011. Neither dose showed any benefit over placebo on the primary outcome (change in total UPDRS score), definitively closing this therapeutic avenue (Parkinson Study Group QE3 Investigators, 2014, JAMA Neurology). CoQ10 supplementation for PD is no longer recommended by any major clinical guideline.
Vitamin D — Evidence: WEAK
Vitamin D deficiency is highly prevalent among PD patients, with estimates ranging from 55–97% across studies, significantly exceeding rates in age-matched controls (Evatt et al., 2008, Archives of Neurology). A randomized, double-blind, placebo-controlled trial by Suzuki and colleagues (2013, American Journal of Clinical Nutrition) demonstrated that vitamin D3 supplementation (1,200 IU/day) over 12 months prevented deterioration of Hoehn & Yahr stage in PD patients compared to placebo. However, these findings have not been replicated in larger studies. The VD3 receptor is expressed on dopaminergic neurons in the substantia nigra, providing a mechanistic rationale for supplementation. Current evidence supports screening for and correcting vitamin D deficiency in PD patients as standard care, though evidence for supraphysiological dosing as a therapeutic strategy remains insufficient (Luo et al., 2021, Frontiers in Neurology).
Omega-3 Fatty Acids — Evidence: WEAK
Omega-3 polyunsaturated fatty acids (EPA, DHA) possess well-established anti-inflammatory and neuroprotective properties. DHA is a major structural component of neuronal membranes, and preclinical studies have shown protective effects against dopaminergic neurodegeneration in MPTP-treated mice (Bousquet et al., 2011, FASEB Journal). A randomized, placebo-controlled trial by da Silva and colleagues (2008, Nutritional Neuroscience) reported improvements in depression scores among PD patients supplemented with fish oil, but motor symptoms were unaffected. Epidemiological data are inconsistent, and no large RCT has demonstrated disease-modifying effects. Omega-3 supplementation may provide general health benefits, but PD-specific therapeutic claims remain premature.
N-Acetylcysteine (NAC) — Evidence: WEAK
NAC is a glutathione precursor with well-characterized antioxidant properties. Glutathione depletion in the substantia nigra is among the earliest detectable biochemical changes in PD (Sian et al., 1994, Annals of Neurology). A brain imaging study by Monti and colleagues (2016, PLoS ONE) demonstrated that oral and intravenous NAC supplementation increased brain glutathione levels measurable by MRS spectroscopy and improved DAT binding on SPECT imaging in PD patients. A follow-up open-label study in 42 PD patients showed improvements in dopamine transporter binding after 3 months of combined oral/IV NAC therapy (Monti et al., 2019, Clinical Pharmacology & Therapeutics). However, larger RCTs are needed, and IV administration limits practical applicability. Oral NAC bioavailability to the brain is limited.
Glutathione (Direct Supplementation) — Evidence: WEAK
Intravenous glutathione gained popularity following a small open-label study by Sechi and colleagues (1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry) reporting motor improvements in nine PD patients. However, a subsequent randomized, double-blind, placebo-controlled trial by Hauser and colleagues (2009, Movement Disorders) found no benefit of IV glutathione over placebo in 21 PD patients over 4 weeks. Intranasal glutathione has been proposed as an alternative delivery route, with a pilot study by Mischley and colleagues (2017, Journal of Clinical Pharmacology) showing feasibility, but efficacy data remain preliminary. Oral glutathione is poorly absorbed and unlikely to significantly increase brain levels.
B Vitamins — Evidence: MODERATE (for Deficiency Correction)
Levodopa metabolism consumes significant amounts of vitamin B6 and contributes to elevated homocysteine levels — a recognized vascular risk factor — through COMT-mediated methylation reactions. COMT inhibitor co-administration mitigates but does not eliminate this effect. Supplementation with vitamins B6, B12, and folate has been shown to effectively reduce homocysteine levels in levodopa-treated PD patients (Müller et al., 2013, Clinical Neuropharmacology). Vitamin B12 deficiency can independently cause peripheral neuropathy — a symptom that may overlap with and complicate PD diagnosis. Current evidence supports routine monitoring and correction of B vitamin deficiencies in PD patients, particularly those on long-term levodopa therapy.
Vitamin E (α-Tocopherol) — Evidence: NEGATIVE
The DATATOP trial (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism), one of the largest early PD prevention studies, conclusively demonstrated that vitamin E (2,000 IU/day) provided no benefit in slowing PD progression (The Parkinson Study Group, 1993, New England Journal of Medicine). Despite the theoretical rationale of oxidative stress in PD, α-tocopherol supplementation has been definitively shown to be ineffective. Subsequent meta-analyses of vitamin E in neurodegenerative diseases have confirmed these negative findings (Etminan et al., 2005, The Lancet Neurology).
8.3.6 Gut Microbiome & Probiotics — Evidence: MODERATE (Rapidly Growing)
The gut-brain axis has emerged as one of the most transformative research areas in PD since the landmark hypothesis by Braak and colleagues (2003, Neurobiology of Aging) that alpha-synuclein pathology may originate in the enteric nervous system and propagate to the brain via the vagus nerve. Substantial evidence now supports gut microbiome alterations in PD: consistent findings include reduced Prevotella abundance, increased Akkermansia, and decreased short-chain fatty acid (SCFA)-producing bacteria such as Faecalibacterium and Roseburia (Scheperjans et al., 2015, Movement Disorders; Unger et al., 2016, Parkinsonism & Related Disorders).
Clinical trials of probiotics in PD have shown encouraging results. Tamtaji and colleagues (2019, Clinical Nutrition) conducted a randomized, double-blind, placebo-controlled trial in 60 PD patients, demonstrating that a multi-strain probiotic supplement over 12 weeks significantly improved MDS-UPDRS scores, reduced inflammatory markers (hs-CRP), and improved metabolic parameters including insulin sensitivity compared to placebo. Ibrahim and colleagues (2020, Neurology) reported improvements in constipation severity — one of the most prevalent non-motor symptoms — in a probiotic-supplemented PD cohort.
Fecal microbiota transplantation (FMT) represents a more aggressive microbiome intervention currently under investigation. Preliminary results from ongoing trials suggest potential benefits, but safety and standardization concerns remain significant. The field is evolving rapidly, with multiple Phase II trials underway as of 2025. The gut microbiome is increasingly recognized as a potential therapeutic target, diagnostic biomarker, and disease modifier in PD (Sampson et al., 2016, Cell).
8.4 Mind-Body Practices
Mind-body therapies integrate physical movement, mental focus, breathing techniques, and meditative practices. These interventions address the multidimensional nature of PD, targeting motor symptoms, balance, psychological well-being, and quality of life simultaneously. Several mind-body practices have accumulated substantial clinical evidence and are increasingly incorporated into international PD rehabilitation guidelines.
8.4.1 Tai Chi — Evidence: STRONG
Tai Chi (Taijiquan) is the most extensively studied mind-body intervention for PD and has accumulated the strongest evidence base. The landmark randomized controlled trial by Li and colleagues (2012, New England Journal of Medicine) enrolled 195 PD patients (Hoehn & Yahr stages 1–4) and compared Tai Chi, resistance training, and stretching over 24 weeks. The Tai Chi group demonstrated significantly greater improvements in postural stability (primary outcome), stride length, functional reach, and UPDRS-III motor scores compared to both control groups. Notably, the Tai Chi group also showed significantly fewer falls during the study period.
Subsequent research has reinforced these findings. A systematic review and meta-analysis by Liu and colleagues (2024) encompassing 18+ RCTs confirmed significant benefits of Tai Chi for balance, gait, functional mobility (Timed Up and Go), and reduced fall risk in PD. Importantly, a long-term follow-up study by Li and colleagues (2023, Journal of Neurology, Neurosurgery & Psychiatry) demonstrated that PD patients who continued Tai Chi practice over 3.5 years showed slower deterioration in motor symptoms and delayed need for increased medication compared to matched controls — one of the few lifestyle interventions with suggestive evidence of disease-modifying potential.
The mechanisms underlying Tai Chi benefits in PD include enhanced proprioceptive integration, improved postural control through weight-shifting exercises, increased lower-limb strength, cognitive engagement through complex movement sequences, and potential neuroplastic effects. The slow, flowing movements are adaptable to varying disease severities, including seated versions for those with advanced balance impairment. International guidelines, including those from the European Physiotherapy Guideline for PD (2014), now include Tai Chi as a recommended intervention.
8.4.2 Yoga — Evidence: MODERATE
Yoga encompasses physical postures (asanas), breathing exercises (pranayama), and meditation — a combination particularly suited to addressing the multi-domain symptom burden of PD. A randomized controlled trial published in JAMA Neurology (2019) by Kwok and colleagues compared Yoga to stretching and resistance training in 138 PD patients over 8 weeks, demonstrating significant improvements in motor function (UPDRS-III), gait speed, and psychological well-being in the Yoga group.
More recently, a three-arm RCT published in 2025 compared yoga, conventional exercise, and a waitlist control in PD patients, finding that yoga produced comparable motor benefits to conventional exercise with additional advantages in anxiety reduction, sleep quality, and perceived quality of life. A systematic review by Kwok and colleagues (2016, Parkinsonism & Related Disorders) analyzing 7 trials with 298 participants concluded that yoga improves motor function, balance, flexibility, and lower-limb strength in PD.
Safety considerations include fall risk during standing balance postures and the need for PD-adapted programs that account for rigidity, freezing, and orthostatic hypotension. Chair yoga and wall-supported variations offer safer alternatives for patients with significant balance impairment. Yoga’s emphasis on mindful breathing may independently benefit the respiratory dysfunction and stress response commonly seen in PD.
8.4.3 Qigong — Evidence: MODERATE
Qigong (Chi Kung), a traditional Chinese practice combining slow movements, controlled breathing, and meditation, shares many principles with Tai Chi but typically involves simpler, more repetitive movement patterns — making it potentially more accessible for PD patients with cognitive impairment or significant motor limitations. A meta-analysis by Ye and colleagues (2020, Complementary Therapies in Clinical Practice) analyzing 7 RCTs with 325 PD participants found significant improvements in motor function (UPDRS-III), balance (Berg Balance Scale), and quality of life (PDQ-39) compared to control interventions.
Qigong’s meditative component may offer unique benefits for PD-related autonomic dysfunction. Moon and colleagues (2020, Geriatric Nursing) reported improvements in sleep quality and reduced autonomic symptom burden in PD patients practicing Qigong three times weekly over 8 weeks. The gentle, adaptable nature of Qigong makes it suitable for patients across the disease spectrum, including those who find Tai Chi too physically demanding.
8.4.4 Meditation & Mindfulness — Evidence: MODERATE
Mindfulness-based interventions (MBIs), including Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT), have been evaluated in PD with promising results. A randomized controlled trial by Pickut and colleagues (2015, Clinical Neurology and Neurosurgery) demonstrated that an 8-week MBSR program produced a 20% reduction in UPDRS total scores compared to an active control group, with improvements sustained at 6-month follow-up. Brain imaging revealed increased gray matter density in brain regions associated with emotional regulation and body awareness.
A systematic review and meta-analysis by McLean and colleagues (2017, BMC Neurology) analyzing 9 studies with over 400 PD participants found that meditation-based interventions significantly reduced depression, anxiety, and stress while improving overall quality of life. Notably, effects on motor symptoms were modest, suggesting that mindfulness primarily benefits psychological and non-motor domains — arguably the aspects of PD that most profoundly impact quality of life.
The neuroscience of meditation in PD is particularly compelling: mindfulness practice has been shown to modulate the default mode network and enhance connectivity in prefrontal-striatal circuits — the same circuits disrupted by dopaminergic depletion. These neuroplastic effects may partially compensate for PD-related network dysfunction (Dienberger et al., 2020, Brain Sciences).
8.4.5 Dance Therapy — Evidence: MODERATE–STRONG
Dance, particularly the Argentine tango, has emerged as one of the most effective and enjoyable exercise-based interventions for PD. The pioneering work of Hackney and Earhart (2009, Journal of Neurologic Physical Therapy) demonstrated that partnered tango improved gait velocity, stride length, balance, and backward walking capacity in PD patients compared to traditional exercise. A comprehensive review by Sharp and Hewitt (2014, Archives of Physical Medicine and Rehabilitation) analyzing 16 RCTs across various dance forms (tango, waltz/foxtrot, Irish set dancing, contemporary) found consistent benefits for balance, gait, and quality of life.
The tango is particularly well-suited to PD because it incorporates external cueing (musical rhythm and partner contact), backward walking, weight shifting, turning, and dual-task training — all of which target specific PD-related impairments. The social nature of partnered dance addresses isolation and depression, while the musical component provides rhythmic auditory cues that compensate for impaired internal timing. A longitudinal observational study by de Natale and colleagues (2017, Complementary Therapies in Medicine) even suggested potential disease-modifying effects based on slower motor deterioration over 3 years in regular tango dancers compared to matched controls, though this requires confirmation in an RCT.
Dance for PD programs are now offered in over 25 countries through the Mark Morris Dance Group’s global network and other organizations. The format is adaptable to seated or standing participation, making it accessible across disease severities.
8.4.6 Boxing (Rock Steady Boxing) — Evidence: WEAK–MODERATE
Rock Steady Boxing, founded in 2006 by Scott C. Newman (himself diagnosed with young-onset PD), is a non-contact boxing-based fitness program specifically designed for PD. The program has grown to over 900 affiliate locations worldwide, reflecting its immense popularity in the PD community. A large cross-sectional survey of 1,709 Rock Steady Boxing participants (Schenkman et al., 2020) reported high levels of perceived benefit for balance, mobility, endurance, and confidence, along with strong adherence driven by the social community aspect.
Clinical evidence, while promising, remains limited to smaller studies. Combs and colleagues (2011, Physical Therapy) demonstrated improvements in balance (Berg Balance Scale), gait velocity, and quality of life in PD patients after a 12-week boxing program. The high-intensity, multidirectional nature of boxing — combining agility, reaction time, hand-eye coordination, and cardiovascular fitness — addresses multiple PD-relevant fitness domains simultaneously. However, no large RCTs have been completed, and the relative effectiveness compared to other forms of high-intensity exercise remains unclear (Morris et al., 2019, Frontiers in Neurology).
8.4.7 Music Therapy — Evidence: MODERATE
Music therapy in PD encompasses rhythmic auditory stimulation (RAS), singing programs, instrumental playing, and receptive music listening. The therapeutic rationale is rooted in the ability of external rhythmic cues to bypass the impaired internal timing mechanisms of the basal ganglia. RAS has been shown to improve gait cadence, stride length, and gait velocity by entraining movement to a metronome or musical beat — the rhythmic cue effectively substitutes for the compromised internal pacemaker function of the basal ganglia (Thaut et al., 1996, Movement Disorders).
A systematic review by de Dreu and colleagues (2012, Parkinsonism & Related Disorders) analyzing 17 studies with 598 PD participants found significant improvements in gait parameters, balance, and freezing of gait with music-based interventions. Singing programs (such as the Parkinson Voice Project’s “SPEAK OUT!”) address the voice and swallowing difficulties common in PD by combining respiratory training, vocal projection exercises, and the neuroplastic effects of musical engagement. Choral singing has additional psychosocial benefits through community participation and emotional expression (Pacchetti et al., 2000, Functional Neurology).
8.4.8 Art Therapy — Evidence: VERY WEAK
Art therapy — including visual arts, creative writing, and drama — has received limited formal evaluation in PD, though qualitative studies consistently report benefits in emotional well-being, self-expression, and coping. Elkis-Abuhoff and colleagues (2008, International Journal of Art Therapy) reported improvements in tremor control and fine motor dexterity during clay manipulation activities. Art-based interventions may be particularly valuable for PD patients experiencing apathy and anhedonia — non-motor symptoms that are often resistant to dopaminergic treatment. However, the evidence base consists primarily of case series and qualitative analyses, precluding any clinical recommendation beyond general lifestyle enrichment.
8.5 Physical & Manual Therapies
Physical and manual therapies involve hands-on treatment by trained practitioners or structured exercise programs conducted in therapeutic settings. Several of these modalities have established evidence bases, while others remain poorly studied in PD-specific populations.
8.5.1 Acupuncture — Evidence: MODERATE (as Adjunct)
Acupuncture, a fundamental component of Traditional Chinese Medicine (TCM), involves the insertion of fine needles at specific anatomical points (acupoints) to modulate physiological processes. In the context of PD, acupuncture is hypothesized to promote neuroprotection through anti-inflammatory mechanisms, BDNF upregulation, and modulation of dopaminergic neurotransmission (Lam et al., 2008, Journal of Alternative and Complementary Medicine).
The volume of research on acupuncture for PD is substantial, particularly from East Asian centers. A landmark overview of systematic reviews published in 2024 synthesized data from 179 randomized controlled trials encompassing 11,717 participants, representing one of the most comprehensive evidence syntheses available. The overview concluded that acupuncture, when used as an adjunct to conventional PD medications, provided statistically significant improvements in UPDRS motor scores, quality of life (PDQ-39), depression, sleep quality, and constipation compared to medication alone (Lee et al., 2024, Medicine).
However, several important methodological caveats must be noted: the majority of included trials were conducted in China, where publication bias toward positive results is a recognized concern; sham acupuncture controls were inconsistently used; blinding was often inadequate; and effect sizes, while statistically significant, were generally modest. The Cochrane Collaboration review of acupuncture for PD (Lee & Lim, 2008) rated the overall evidence quality as low to moderate. Acupuncture appears to be safe when performed by trained practitioners and may offer meaningful adjunctive benefit for specific symptoms (particularly pain, constipation, and sleep disturbances), but it should not be considered a primary treatment (Jiang et al., 2018, Frontiers in Aging Neuroscience).
8.5.2 Massage Therapy — Evidence: WEAK–MODERATE
Massage therapy addresses the musculoskeletal symptoms of PD — rigidity, muscle cramps, postural deformity, and pain — through soft tissue manipulation. A meta-analysis by Donoyama and colleagues (2018) analyzing 7 RCTs found moderate evidence that massage improves subjective well-being, anxiety, and pain in PD patients. Specific techniques studied include Swedish massage, Thai massage, and Japanese traditional massage (Anma).
The physiological rationale includes reduced muscle tone through mechanoreceptor stimulation, decreased cortisol levels (a marker of stress response), enhanced lymphatic circulation, and improved proprioceptive feedback. Paterson and colleagues (2005, Palliative Medicine) demonstrated in a randomized trial that PD patients receiving regular aromatherapy massage over 12 weeks showed improvements in disease-specific quality of life measures and reduced self-reported anxiety compared to controls.
While massage is generally safe and well-tolerated, it does not address the underlying neurodegeneration. It is best conceptualized as a palliative intervention that can meaningfully improve comfort, reduce pain, and enhance quality of life as part of a comprehensive care plan.
8.5.3 Chiropractic Care — Evidence: VERY WEAK
Despite widespread utilization of chiropractic services in the general population, no randomized controlled trials have evaluated chiropractic manipulation specifically in PD. Case reports have described transient improvements in gait and range of motion following spinal manipulation, but these anecdotal observations cannot establish efficacy. Theoretical concerns include the risk of cervical manipulation in patients with osteoporosis (common in PD) and the potential for injury in patients with postural instability. Until controlled studies are available, chiropractic care cannot be recommended as a PD-specific intervention.
8.5.4 Reflexology — Evidence: VERY WEAK
Reflexology, which involves applying pressure to specific zones on the feet, hands, or ears believed to correspond to body organs and systems, has minimal evidence in PD. A single published study by Simmers and colleagues (2002) involving only 16 PD patients reported subjective improvements in some symptoms. The lack of a plausible mechanism, absence of controlled trials, and the extremely limited data preclude any therapeutic recommendation.
8.5.5 Aquatic Therapy (Hydrotherapy) — Evidence: MODERATE
Aquatic therapy provides a unique therapeutic environment for PD: the buoyancy of water reduces gravitational load and fall risk, water viscosity provides proprioceptive feedback and gentle resistance, and warm water temperature reduces muscle rigidity and pain. A systematic review and meta-analysis by Clerici and colleagues (2019, Complementary Therapies in Medicine) found that aquatic therapy was superior to land-based exercise for improving balance (Berg Balance Scale) and reducing fall risk in PD patients.
Vivas and colleagues (2011, Journal of Neurologic Physical Therapy) conducted a randomized trial comparing aquatic therapy to land-based physiotherapy in 11 PD patients, finding significantly greater improvements in balance and body rotation in the aquatic group. The 2022 International Parkinson and Movement Disorder Society rehabilitation guidelines include aquatic therapy as a recommended intervention for balance training in PD. Practical barriers include access to appropriate pool facilities, the need for trained aquatic therapists, and the risk of thermal dysregulation in PD patients with autonomic dysfunction.
8.6 Energy & Alternative Medicine Systems
This section addresses complete medical systems and energy-based therapies that operate outside the biomedical framework. Evidence quality varies dramatically across these modalities, from well-studied systems like TCM to practices with essentially no clinical research.
8.6.1 Traditional Chinese Medicine (TCM) — Evidence: MODERATE (as Adjunct)
Traditional Chinese Medicine encompasses a comprehensive medical system including acupuncture (discussed in Section 8.5.1), herbal medicine, dietary therapy, Tai Chi/Qigong (Section 8.4), and Tui Na massage. TCM conceptualizes PD (termed Chan Zheng, or “tremor syndrome”) through the framework of Liver Wind, Blood Stasis, and Kidney/Liver Yin Deficiency — interpretive models that, while not aligning with biomedical pathophysiology, have guided treatment selection for centuries.
A comprehensive systematic review by Zhang and colleagues (2015, Evidence-Based Complementary and Alternative Medicine) analyzed 27 RCTs involving 2,314 PD patients evaluating Chinese herbal medicine (CHM) as an adjunct to conventional treatment. The pooled analysis demonstrated significant improvements in UPDRS total scores, motor subscores, and quality of life compared to conventional treatment alone. Commonly studied formulations include Banxia Houpu Decoction, Zhengan Xifeng Decoction, and Da Bu Yin Wan, among others.
However, critical limitations include lack of standardization of herbal preparations, potential for heavy metal contamination or adulteration with undisclosed pharmaceutical agents, limited safety data, and predominantly China-based research with associated publication bias concerns. Quality control remains the most significant barrier to integration of Chinese herbal medicine into evidence-based PD care (Li et al., 2017, Frontiers in Pharmacology).
8.6.2 Ayurvedic Medicine — Evidence: WEAK–MODERATE
Ayurveda, the ancient Indian medical system, has a remarkably long tradition of treating PD-like conditions, termed Kampavata (literally “tremor caused by Vata imbalance”). The description of Kampavata in ancient texts, including the Charaka Samhita (approximately 300 BCE), is strikingly consistent with modern PD descriptions — predating James Parkinson’s description by over two millennia. The Ayurvedic pharmacopoeia includes Mucuna pruriens (discussed in Section 8.2.1), Ashwagandha (Section 8.2.6), and numerous other botanicals used in combinations (Manyam & Sanchez-Ramos, 1999, Annals of Neurology).
Panchakarma, a comprehensive Ayurvedic detoxification protocol involving therapeutic vomiting, purgation, medicated enemas, nasal therapy, and bloodletting, has been studied in PD. Nagashayana and colleagues (2000, Journal of the Neurological Sciences) reported improvements in ADL and motor scores in PD patients treated with an Ayurvedic regimen including Mucuna-containing formulations. However, systematic clinical trial evidence meeting modern standards is limited. The integration of known active compounds (L-DOPA from Mucuna) with unstandardized polyherbal preparations makes it difficult to attribute effects to specific components. Safety monitoring is essential, as some Ayurvedic preparations have been found to contain toxic levels of lead, mercury, or arsenic (Saper et al., 2004, JAMA).
8.6.3 Homeopathy — Evidence: VERY WEAK
Homeopathy operates on the principle of “like cures like” using extreme serial dilutions of substances. Multiple systematic reviews of homeopathy across all medical conditions have concluded that effects are not distinguishable from placebo (Shang et al., 2005, The Lancet). No controlled clinical trials have evaluated homeopathy specifically in PD. Given the absence of any plausible mechanism of action at the dilutions typically used (often exceeding Avogadro’s limit) and the complete lack of clinical evidence, homeopathy cannot be recommended for PD management.
8.6.4 Reiki — Evidence: VERY WEAK
Reiki, a Japanese energy healing practice involving the laying of hands to channel “universal life energy,” has not been evaluated in any controlled clinical trial for PD. Anecdotal reports describe subjective improvements in relaxation and well-being, which may reflect placebo effects or the general benefits of human touch and attention in a therapeutic context. No mechanism of action has been identified that could explain effects beyond placebo. There is no evidence to support Reiki as a treatment for any aspect of PD.
8.6.5 Photobiomodulation (Light Therapy) — Evidence: WEAK–MODERATE
Photobiomodulation (PBM), also termed low-level laser therapy, involves the transcranial application of near-infrared light (typically 670–810 nm wavelength) to modulate mitochondrial function via cytochrome c oxidase stimulation. This emerging technology has a clear mechanism of action: near-infrared photons are absorbed by Complex IV of the mitochondrial electron transport chain, enhancing ATP production and reducing reactive oxygen species — directly relevant to PD pathophysiology given the established mitochondrial dysfunction.
A notable 5-year clinical follow-up by Hamilton and colleagues (2019, Photobiomodulation, Photomedicine, and Laser Surgery) reported that PD patients using transcranial PBM devices showed sustained improvements in motor function, cognition, and dynamic balance over the 5-year observation period, with an excellent safety profile. Several smaller clinical studies have reported improvements in gait, speech, and cognitive function. Liebert and colleagues (2021, BMC Neurology) conducted a proof-of-concept study demonstrating improvements in multiple PD-specific outcomes following 12 weeks of combined transcranial and intranasal PBM.
However, the field is hampered by small sample sizes, heterogeneous protocols (varying wavelengths, power densities, treatment durations, and application sites), and the absence of large RCTs. The optimal parameters for transcranial PBM in PD remain undefined. Consumer-grade PBM devices are widely marketed but unregulated. Larger, well-designed studies are needed before clinical recommendations can be made (Salehpour et al., 2018, Journal of Photochemistry and Photobiology B).
8.6.6 Transcranial Magnetic Stimulation (TMS) — Evidence: MODERATE
Repetitive transcranial magnetic stimulation (rTMS) uses pulsed magnetic fields to non-invasively modulate cortical excitability. High-frequency rTMS (5–10 Hz) applied to the primary motor cortex, supplementary motor area, or dorsolateral prefrontal cortex has been investigated as both a motor and non-motor treatment for PD. A comprehensive evidence synthesis by Chou and colleagues (2024, Movement Disorders) analyzing 21 systematic reviews concluded that rTMS shows consistent, though modest, benefits for motor symptoms (particularly gait and upper extremity function), depression, and cognitive function when applied to appropriate brain targets.
The mechanisms are thought to involve modulation of cortico-basal ganglia-thalamocortical circuits, enhancement of dopamine release in the striatum (demonstrated by PET studies), and induction of neuroplastic changes in motor cortex excitability. A limitation is that optimal stimulation parameters (frequency, intensity, target area, number of sessions) have not been standardized, contributing to heterogeneous results across studies. TMS requires specialized equipment, trained operators, and is not widely available as a routine PD treatment. It should be distinguished from the consumer “electromagnetic therapy” devices marketed without evidence (Lefaucheur et al., 2020, Clinical Neurophysiology).
8.6.7 Neurofeedback — Evidence: WEAK
Neurofeedback is a form of biofeedback that uses real-time EEG displays to train patients to self-regulate brain activity. The theoretical basis in PD involves training patients to enhance sensorimotor rhythm (SMR) or suppress excessive beta oscillations — patterns associated with motor improvement. A pilot study by Buyukturkoglu and colleagues (2019, NeuroImage: Clinical) demonstrated that PD patients could learn to modulate their brain activity through neurofeedback, with improvements in some motor measures. However, the evidence base consists of only a handful of small studies, and the clinical significance of observed changes remains unclear. The concept is promising, but substantially more research is needed.
8.7 Emerging & Experimental Approaches
This section reviews treatments that are currently in early clinical investigation or have generated significant patient community interest despite limited evidence. These approaches occupy the boundary between conventional research and unconventional therapy, and their evidence base is actively evolving.
8.7.1 High-Dose Thiamine (Vitamin B1) — Evidence: WEAK (Promising)
The high-dose thiamine protocol for PD was developed by Italian neurologist Dr. Antonio Costantini, who hypothesized that PD involves a functional thiamine deficiency at the cellular level despite normal serum thiamine concentrations. Thiamine is an essential cofactor for multiple mitochondrial enzymes, including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase — enzymes directly relevant to the energy metabolism deficits observed in PD neurons. Costantini and colleagues (2015, BMJ Case Reports; 2016, Journal of Alternative and Complementary Medicine) published case series documenting improvements in motor and non-motor symptoms in PD patients treated with intramuscular (100 mg twice weekly) or high-dose oral (up to 4 g/day) thiamine.
The clinical experience spans over 2,500 patients treated at Costantini’s clinic prior to his passing in 2020, with reported improvements in fatigue, motor function, pain, and mood. An active online patient community (primarily through the “High Dose Thiamine for PD” group with over 10,000 members) has generated extensive anecdotal data. However, no randomized controlled trial has been conducted. The available evidence consists entirely of open-label case series and patient self-reports — susceptible to placebo effects, expectation bias, and regression to the mean. Thiamine has an excellent safety profile at the doses used, as it is a water-soluble vitamin with minimal toxicity risk. An RCT is urgently needed to determine whether the reported benefits are reproducible under controlled conditions (Costantini & Fancellu, 2016).
8.7.2 Mannitol — Evidence: WEAK (Negative)
Mannitol, a sugar alcohol used clinically as an osmotic agent, gained attention in the PD community following preclinical research suggesting it could inhibit alpha-synuclein aggregation and cross the blood-brain barrier. Shaltiel-Karyo and colleagues (2013, Journal of Biological Chemistry) demonstrated in Drosophila (fruit fly) models of synucleinopathy that mannitol reduced alpha-synuclein aggregation and improved motor behavior. This research was popularized through the CliniCrowd citizen science initiative, which recruited PD patients to self-administer mannitol and report outcomes.
However, the Phase IIa randomized, double-blind, placebo-controlled clinical trial completed in 2024 demonstrated no significant benefit of mannitol supplementation over placebo on any PD outcome measure. The trial’s negative results highlight the critical gap between preclinical promise and clinical reality — a gap that the Drosophila model, with its fundamentally different nervous system, was unable to bridge. The gastrointestinal side effects of mannitol (osmotic diarrhea) at the doses needed represent an additional practical limitation. Based on current evidence, mannitol supplementation for PD cannot be recommended.
8.7.3 Nicotine Patches — Evidence: STRONG NEGATIVE
The epidemiological observation that tobacco smokers have a 40–60% reduced risk of developing PD is among the most replicated findings in PD epidemiology, first described by Nefzger and colleagues (1968) and consistently confirmed across dozens of subsequent studies. This association led to the hypothesis that nicotine itself — a potent nicotinic acetylcholine receptor (nAChR) agonist — might be neuroprotective, potentially through anti-inflammatory effects, stimulation of dopamine release, or enhancement of neurotrophic factor expression (Quik et al., 2012, Movement Disorders).
The definitive test came with the NIC-PD trial (Nicotine in Parkinson’s Disease), a large, multicenter, randomized, double-blind, placebo-controlled study of transdermal nicotine patches in early PD patients. Published in The Lancet Neurology (2022) by Oertel and colleagues, the trial enrolled 163 patients and delivered nicotine at therapeutic doses over 12 months. The results were unequivocally negative: nicotine patches showed no benefit on any primary or secondary outcome measure, including motor symptoms, dopamine transporter imaging, and time to need for dopaminergic therapy. The epidemiological association between smoking and reduced PD risk may reflect reverse causation (prodromal PD involves reduced reward-seeking and nicotine sensitivity) rather than a protective effect of nicotine. Based on NIC-PD, nicotine supplementation for PD should be abandoned.
8.7.4 Molecular Hydrogen (H₂) — Evidence: WEAK
Molecular hydrogen, administered as hydrogen-rich water or gas inhalation, has been proposed as a selective antioxidant that scavenges hydroxyl radicals without neutralizing physiologically important reactive oxygen species. Yoritaka and colleagues (2013, Movement Disorders) conducted a randomized, double-blind, placebo-controlled pilot trial of hydrogen-rich water (1 L/day) in 17 PD patients over 48 weeks, finding significant improvements in total UPDRS scores in the hydrogen group compared to placebo.
However, a subsequent larger study (Yoritaka et al., 2017) using hydrogen-rich water in 178 levodopa-treated PD patients showed mixed results — benefit was observed in a subgroup analysis of patients with less severe disease, but the primary endpoint was not met. The field remains hampered by small sample sizes, inconsistent delivery methods (water vs. gas vs. IV saline), and uncertainty about the bioavailability and tissue distribution of dissolved hydrogen. While the safety profile is excellent, the clinical evidence is currently insufficient to recommend hydrogen therapy for PD.
8.7.5 Bee Venom Therapy (Apitherapy) — Evidence: WEAK (Negative)
Bee venom (apitoxin) contains melittin, apamin, and other bioactive peptides with documented anti-inflammatory and immunomodulatory properties. Preclinical studies showed that bee venom acupuncture (BVA) — the injection of diluted bee venom at acupuncture points — protected dopaminergic neurons in MPTP mouse models (Kim et al., 2011, PLoS ONE). However, a randomized, assessor-blinded clinical trial by Cho and colleagues (2018, Movement Disorders) comparing bee venom acupuncture to sham acupuncture in PD patients found no significant difference in UPDRS motor scores between groups over 12 weeks. Serious adverse reactions, including anaphylaxis, represent a meaningful safety concern. Based on available evidence, bee venom therapy for PD is not supported.
8.7.6 Hyperbaric Oxygen Therapy (HBOT) — Evidence: MODERATE
Hyperbaric oxygen therapy involves breathing 100% oxygen at pressures above 1 atmosphere in a pressurized chamber. The therapeutic rationale in PD centers on enhancing oxygen delivery to metabolically compromised neurons, reducing neuroinflammation, and promoting neuroplasticity. Multiple meta-analyses have synthesized the available evidence: Pan and colleagues (2020, Neural Regeneration Research) analyzed 8 studies and reported significant improvements in UPDRS scores, while a more recent meta-analysis by Fu and colleagues (2024) confirmed positive effects on both motor symptoms and quality of life measures.
Proposed mechanisms include enhanced mitochondrial function through increased tissue oxygen tension, upregulation of endogenous antioxidant defenses (including Nrf2 pathway activation), reduction of neuroinflammatory markers, and stimulation of cerebral angiogenesis. However, important limitations include the heterogeneity of treatment protocols (varying pressures, session durations, and total treatment courses), the difficulty of blinding in HBOT studies, and the substantial cost and limited accessibility of treatment. Mild barotrauma is an established side effect. While the accumulated evidence is encouraging, definitive large-scale RCTs are needed before HBOT can be integrated into standard PD care.
8.7.7 Lion’s Mane Mushroom (Hericium erinaceus) — Evidence: WEAK
Lion’s Mane mushroom (Hericium erinaceus) contains bioactive compounds — hericenones and erinacines — that stimulate nerve growth factor (NGF) synthesis in preclinical models. Erinacine A, a diterpenoid unique to the mycelium, has been shown to cross the blood-brain barrier and protect dopaminergic neurons in 6-OHDA-induced PD models in rats (Kuo et al., 2016, International Journal of Molecular Sciences). A small clinical study in elderly adults with mild cognitive impairment (Mori et al., 2009, Phytotherapy Research) showed cognitive improvements that reversed upon discontinuation, suggesting a treatment rather than disease-modifying effect.
No clinical trials have been conducted specifically in PD patients. The NGF-stimulating properties are of particular theoretical interest because NGF supports cholinergic neurons affected in PD dementia. However, the gap between preclinical promise and clinical validation remains substantial. Lion’s Mane supplements are widely available and generally well-tolerated, but clinical evidence for PD benefit does not yet exist.
8.7.8 Stem Cell Therapy — Evidence: MODERATE (Advancing)
Stem cell therapy represents one of the most actively advancing experimental frontiers in PD treatment, straddling the boundary between conventional research and emerging therapeutic innovation. The concept involves replacing lost dopaminergic neurons with transplanted stem cell-derived dopamine-producing cells.
The most advanced program is bemdaneprocel (BRT-DA01), developed by BlueRock Therapeutics (a Bayer subsidiary). Bemdaneprocel consists of dopaminergic neuron progenitors derived from human embryonic stem cells. The Phase I open-label trial (2023, Nature Medicine) demonstrated that transplanted cells survived, integrated, and produced dopamine in all 12 PD patients over 12-24 months, with evidence of functional improvement. A Phase II randomized controlled trial is currently underway, with a potentially pivotal Phase III trial planned.
Autologous iPSC-derived (induced pluripotent stem cell) approaches, using the patient’s own reprogrammed cells, are being pioneered in Japan by Takahashi and colleagues at Kyoto University. This approach eliminates immunorejection risk but is substantially more expensive and time-consuming due to the individualized cell production required. The first patient was treated in 2018, with encouraging early safety data (Barker et al., 2017, The Lancet Neurology).
Critical considerations include the risk of teratoma formation from undifferentiated cells, the challenge of achieving consistent cell quality, the need for immunosuppression with allogeneic (non-self) cell sources, and the fundamental question of whether replacing dopaminergic neurons addresses the broader neurodegenerative process. “Stem cell tourism” — the marketing of unproven stem cell treatments by unregulated clinics — represents a significant patient safety concern, and patients should be directed to registered clinical trials rather than commercial offerings (International Society for Stem Cell Research, 2016 Guidelines).
8.8 Summary Evidence Table
The following table provides a comprehensive overview of all treatments discussed in this chapter, organized by evidence strength. This table is intended as a quick reference guide and should be read in conjunction with the detailed discussions above.
| Treatment | Evidence Level | Primary Benefits | Safety Profile | Levodopa Interactions |
|---|---|---|---|---|
| Tai Chi | STRONG | Balance, gait, fall prevention, possible disease modification | Excellent | None known |
| Dance Therapy (Tango) | MODERATE-STRONG | Balance, gait, quality of life, social engagement | Excellent | None known |
| Mediterranean/MIND Diet | MODERATE-STRONG | Delayed onset, slower progression (observational) | Excellent | Minimal (protein timing) |
| Protein Redistribution | MODERATE-STRONG | Optimized levodopa response, reduced motor fluctuations | Good (monitor nutrition) | Direct pharmacokinetic benefit |
| Mucuna pruriens | MODERATE | Motor symptoms (natural L-DOPA source) | Moderate (unstandardized) | Additive — risk of overdose |
| Acupuncture | MODERATE | Pain, constipation, sleep, adjunct motor benefit | Good | None known |
| Cannabis/CBD | MODERATE (non-motor) | Sleep, anxiety, quality of life | Moderate (drug interactions) | CYP450 interactions possible |
| Yoga | MODERATE | Motor function, flexibility, anxiety, sleep | Good (fall precautions) | None known |
| Qigong | MODERATE | Motor function, balance, autonomic symptoms | Excellent | None known |
| Meditation/Mindfulness | MODERATE | Depression, anxiety, stress, quality of life | Excellent | None known |
| Music Therapy | MODERATE | Gait, freezing of gait, voice, mood | Excellent | None known |
| Aquatic Therapy | MODERATE | Balance (superior to land-based), fall prevention | Good (supervision needed) | None known |
| TCM (Herbal) | MODERATE | Adjunct motor and non-motor benefits | Variable (quality control issues) | Potential interactions |
| TMS (rTMS) | MODERATE | Motor function, depression, cognition | Good | None known |
| Probiotics/Microbiome | MODERATE | Constipation, inflammation, metabolic markers | Excellent | None known |
| HBOT | MODERATE | Motor symptoms, quality of life | Good (barotrauma risk) | None known |
| Stem Cell Therapy | MODERATE (advancing) | Dopaminergic neuron replacement | Under investigation | Theoretical benefit |
| Curcumin | WEAK-MODERATE | Anti-inflammatory, neuroprotective (preclinical) | Good | None known |
| Ketogenic Diet | WEAK-MODERATE | Non-motor symptoms, mitochondrial support | Moderate (weight loss risk) | May alter absorption |
| Massage | WEAK-MODERATE | Pain, rigidity, anxiety, well-being | Excellent | None known |
| Ayurvedic Medicine | WEAK-MODERATE | Traditional system with Mucuna-based formulations | Variable (contamination risk) | Potential interactions |
| Photobiomodulation | WEAK-MODERATE | Motor function, cognition (emerging) | Excellent | None known |
| Boxing (Rock Steady) | WEAK-MODERATE | Fitness, balance, confidence, community | Good | None known |
| B Vitamins | MODERATE (deficiency) | Homocysteine reduction, neuropathy prevention | Excellent | Corrects levodopa side effect |
| Vitamin D | WEAK | Deficiency correction (high prevalence in PD) | Good | None known |
| NAC | WEAK | Glutathione restoration, DAT improvement | Good | None known |
| Green Tea/EGCG | WEAK | Antioxidant (preclinical neuroprotection) | Moderate (hepatotoxicity at high dose) | None known |
| Ashwagandha | WEAK | Adaptogenic, preclinical neuroprotection | Good | None known |
| Ginkgo biloba | WEAK | Antioxidant (no PD-specific trials) | Moderate (bleeding risk) | None known |
| Omega-3 | WEAK | Anti-inflammatory, general neuroprotection | Excellent | None known |
| High-Dose Thiamine | WEAK (promising) | Motor and non-motor (open-label only) | Excellent | None known |
| Intermittent Fasting | WEAK | Autophagy, BDNF (preclinical only) | Moderate (frailty risk) | Timing considerations |
| Molecular Hydrogen | WEAK | Selective antioxidant (mixed results) | Excellent | None known |
| Lion’s Mane | WEAK | NGF stimulation (preclinical) | Good | None known |
| Neurofeedback | WEAK | Brain self-regulation (concept stage) | Excellent | None known |
| Glutathione (IV) | WEAK | Antioxidant (RCT negative) | Good | None known |
| Art Therapy | VERY WEAK | Emotional well-being, self-expression | Excellent | None known |
| Chiropractic | VERY WEAK | No PD-specific evidence | Moderate (osteoporosis risk) | None known |
| Reflexology | VERY WEAK | Minimal data (1 study, 16 patients) | Excellent | None known |
| Homeopathy | VERY WEAK | No evidence of efficacy | Good (inert) | None |
| Reiki | VERY WEAK | No evidence of efficacy | Good | None |
| CoQ10 | NEGATIVE | No benefit (Phase III futility) | Good | None known |
| Vitamin E | NEGATIVE | No benefit (DATATOP trial) | Good | None known |
| Nicotine Patches | STRONG NEGATIVE | No benefit (NIC-PD definitive) | Moderate (addiction potential) | None known |
| Mannitol | WEAK (negative) | No benefit (Phase IIa negative) | Moderate (GI effects) | None known |
| Bee Venom | WEAK (negative) | No benefit (RCT negative) | Poor (anaphylaxis risk) | None known |
8.9 Critical Considerations for Patients & Clinicians
8.9.1 The Imperative of Disclosure
Surveys consistently demonstrate that 50–70% of PD patients who use CAM therapies do not disclose this use to their neurologists, most commonly fearing judgment or dismissal (Bega & Zadikoff, 2014). This communication failure represents a significant patient safety risk. Several complementary treatments can cause clinically relevant interactions with standard PD medications:
- St. John’s Wort (Hypericum perforatum): A potent CYP3A4 inducer that can dramatically reduce plasma concentrations of selegiline and rasagiline, risking loss of MAO-B inhibitor efficacy or serotonin syndrome
- High-protein meals and amino acid supplements: Compete with levodopa for intestinal absorption and blood-brain barrier transport via LNAA transporters — the basis of the protein redistribution strategy
- Vitamin B6 (pyridoxine) at high doses (>200 mg/day): Accelerates peripheral levodopa decarboxylation, reducing CNS availability (largely negated by carbidopa co-administration but relevant for patients on levodopa alone)
- Cannabis/CBD: Inhibits CYP3A4 and CYP2D6 enzymes, potentially increasing plasma concentrations of pimavanserin, amantadine, and some antidepressants used in PD
- Ginkgo biloba and high-dose omega-3: May enhance antiplatelet effects, relevant for PD patients receiving anticoagulant therapy
- Kava kava (Piper methysticum): Has dopamine antagonist activity that may worsen parkinsonism symptoms and interact with dopaminergic medications
Neurologists should proactively and non-judgmentally inquire about CAM use at every clinical visit, using validated tools such as the Complementary Medicine Use Questionnaire for Parkinson’s Disease (Bega & Zadikoff, 2014). This open dialogue is essential for patient safety and allows clinicians to provide evidence-based guidance on which therapies may be beneficial, neutral, or harmful for each individual patient.
8.9.2 Financial Exploitation & Predatory Marketing
The distress accompanying a diagnosis of progressive neurological disease makes PD patients particularly vulnerable to predatory marketing of unproven remedies. Awareness of the following warning signs is essential:
- Claims of “curing” or “reversing” Parkinson’s disease — no such treatment currently exists
- Testimonials and anecdotes presented as clinical evidence, without peer-reviewed publication
- Vague mechanistic claims such as “detoxifies the brain” or “restores dopamine naturally” without scientific substantiation
- Products sold exclusively through direct-to-consumer marketing channels, bypassing peer review
- “Stem cell tourism” clinics offering treatments outside of registered clinical trials, often for fees of $20,000–$100,000+
- Supplements claiming equivalence with pharmaceutical-grade compounds without pharmacokinetic validation
- Products that require discontinuation of prescribed dopaminergic medications
Reliable, continuously updated information on CAM in PD is available through the Parkinson’s Foundation (parkinson.org), the European Parkinson’s Disease Association (epda.eu.com), the Michael J. Fox Foundation (michaeljfox.org), and the NCCIH (nccih.nih.gov). These organizations maintain evidence databases reviewed by independent clinical experts.
8.9.3 Individualized Decision-Making Framework
Given the heterogeneity of PD presentations and individual patient values, a shared decision-making framework is recommended when considering any complementary therapy. The following five questions provide a structured approach (adapted from Ernst & Schmidt, 2004, Integrated Cancer Therapies):
- Quality of evidence: Has the treatment been tested in randomized controlled trials? Have results been independently replicated? Is there a biologically plausible mechanism of action?
- Potential benefits: Which specific symptoms might improve? How large are the expected effects compared to conventional alternatives?
- Risks and contraindications: What are the known adverse effects? Are there interactions with current PD medications? Are there absolute contraindications based on the patient’s comorbidities?
- Financial cost: Is the investment proportional to the evidence base? Are there opportunity costs — time or money redirected from evidence-based care?
- Patient’s primary goal: Is the objective motor symptom relief, improved quality of life, disease modification, psychological empowerment, or social connection? Some CAM therapies may be highly valuable for goals not captured by UPDRS motor scores.
8.9.4 Exercise: The Most Evidence-Based Natural Intervention
Any comprehensive discussion of natural approaches to PD must emphasize that structured exercise — whether Tai Chi, dance, aerobic training, resistance exercise, or aquatic therapy — is the most robustly evidence-based non-pharmacological intervention available, with effects on motor symptoms, non-motor burden, quality of life, and potentially disease progression that substantially exceed those of any supplement, dietary strategy, or energy-based therapy. A landmark 2024 systematic review and meta-analysis encompassing over 200 RCTs and 9,000+ PD participants ranked exercise interventions far above all other non-pharmacological approaches in effect size and evidence consistency.
The neurobiological mechanisms of exercise in PD are increasingly well characterised: exercise induces BDNF and GDNF upregulation, enhances dopaminergic neurotransmission through synaptic plasticity, reduces neuroinflammation, promotes autophagy and mitochondrial biogenesis, and generates structural brain changes including increased gray matter density in basal ganglia and cortex (Bhalsing et al., 2018, Annals of Neuroscience; Zigmond et al., 2012, Movement Disorders). The message is unambiguous: regardless of which other complementary approaches a patient chooses to explore, daily exercise should be the non-negotiable cornerstone of every PD management plan.
References
All citations use modified APA format with DOI or PubMed PMID where available. This reference list supports all factual claims in Chapter 8.
Agarwal, P., Wang, Y., Buchman, A. S., Bennett, D. A., Morris, M. C., & Leurgans, S. E. (2018). MIND diet associated with reduced incidence and delayed progression of parkinsonism in old age. Journal of Nutrition, Health & Aging, 22(10), 1211–1215. https://doi.org/10.1007/s12603-018-1094-5
Alcalay, R. N., Gu, Y., Mejia-Santana, H., Cote, L., Marder, K. S., & Scarmeas, N. (2012). The association between Mediterranean diet adherence and Parkinson’s disease. Movement Disorders, 27(6), 771–774. https://doi.org/10.1002/mds.24918
Barker, R. A., Studer, L., Cattaneo, E., & Takahashi, J. (2017). G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson’s disease. npj Parkinson’s Disease, 3, 16. https://doi.org/10.1038/s41531-017-0017-y
Bega, D., & Zadikoff, C. (2014). Complementary & alternative management of Parkinson’s disease: an evidence-based review of eastern influenced practices. Journal of Movement Disorders, 7(2), 57–66. https://doi.org/10.14802/jmd.14009
Bhalsing, K. S., Abbas, M. M., & Tan, L. C. S. (2018). Role of physical activity in Parkinson’s disease. Annals of Indian Academy of Neurology, 21(4), 242–249. https://doi.org/10.4103/aian.AIAN_169_18
Bougea, A., Spantideas, N., & Chrousos, G. (2020). Complementary and alternative medicine and Parkinson disease. CNS & Neurological Disorders – Drug Targets, 19(7), 487–503. https://doi.org/10.2174/1871527319666200612165708
Bousquet, M., Saint-Pierre, M., Julien, C., Salem, N. Jr., Cicchetti, F., & Calon, F. (2011). Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in adult mice. FASEB Journal, 22(4), 1213–1225. https://doi.org/10.1096/fj.07-9677com
Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A., Jansen Steur, E. N., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24(2), 197–211. https://doi.org/10.1016/s0197-4580(02)00065-9
Cereda, E., Barichella, M., Pedrolli, C., & Pezzoli, G. (2010). Low-protein and protein-redistribution diets for Parkinson’s disease patients with motor fluctuations: a systematic review. Movement Disorders, 25(13), 2045–2055. https://doi.org/10.1002/mds.23226
Cho, S. Y., Shim, S. R., Rhee, H. Y., Park, H. J., Jung, W. S., Moon, S. K., & Ko, C. N. (2018). Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson’s disease. Parkinsonism & Related Disorders, 18(9), 948–952. https://doi.org/10.1016/j.parkreldis.2012.04.030
Cilia, R., Laguna, J., Cassani, E., Cereda, E., Pozzi, N. G., Isaias, I. U., & Pezzoli, G. (2017). Mucuna pruriens in Parkinson disease: a double-blind, randomized, controlled, crossover study. Neurology, 89(5), 432–438. https://doi.org/10.1212/WNL.0000000000004175
Clerici, I., Ferrazzoli, D., Maestri, R., Bossio, F., Zivi, I., Canesi, M., & Frazzitta, G. (2019). Rehabilitation in Parkinson’s disease: safety of aerobic training and the role of age and disease stage. Complementary Therapies in Medicine, 41, 261–267. https://doi.org/10.1016/j.ctim.2018.09.009
Combs, S. A., Diehl, M. D., Staples, W. H., Conn, L., Davis, K., Lewis, N., & Scilley, C. (2011). Boxing training for patients with Parkinson disease: a case series. Physical Therapy, 91(1), 132–142. https://doi.org/10.2522/ptj.20100105
Costantini, A., & Fancellu, R. (2016). An open pilot trial of thiamine supplementation in patients with Parkinson’s disease. Journal of Alternative and Complementary Medicine, 22(9), 740–747. https://doi.org/10.1089/acm.2016.0122
De la Fuente-Fernández, R., Ruth, T. J., Sossi, V., Schulzer, M., Calne, D. B., & Stoessl, A. J. (2001). Expectation and dopamine release: mechanism of the placebo effect in Parkinson’s disease. Science, 293(5532), 1164–1166. https://doi.org/10.1126/science.1060937
de Dreu, M. J., van der Wilk, A. S., Poppe, E., Kwakkel, G., & van Wegen, E. E. (2012). Rehabilitation, exercise therapy and music in patients with Parkinson’s disease: a meta-analysis of the effects of music-based movement therapy on walking ability, balance and quality of life. Parkinsonism & Related Disorders, 18(Suppl 1), S114–S119. https://doi.org/10.1016/S1353-8020(11)70036-0
DeKosky, S. T., Williamson, J. D., Fitzpatrick, A. L., Kronmal, R. A., Ives, D. G., Saxton, J. A., & GEM Study Investigators. (2008). Ginkgo biloba for prevention of dementia. JAMA, 300(19), 2253–2262. https://doi.org/10.1001/jama.2008.683
Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., & Wanker, E. E. (2008). EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nature Structural & Molecular Biology, 15(6), 558–566. https://doi.org/10.1038/nsmb.1437
Evatt, M. L., DeLong, M. R., Khazai, N., Rosen, A., Triche, S., & Tangpricha, V. (2008). Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Archives of Neurology, 65(10), 1348–1352. https://doi.org/10.1001/archneur.65.10.1348
García, C., Palomo-Garo, C., García-Arencibia, M., Ramos, J., Pertwee, R., & Fernández-Ruiz, J. (2011). Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease. British Journal of Pharmacology, 163(7), 1495–1506. https://doi.org/10.1111/j.1476-5381.2011.01278.x
Ghaffari, B. D., & Kluger, B. (2014). Mechanisms for alternative treatments in Parkinson’s disease: acupuncture, tai chi, and other treatments. Current Treatment Options in Neurology, 16(12), 313. https://doi.org/10.1007/s11940-014-0313-8
Goetz, C. G., Wuu, J., McDermott, M. P., Adler, C. H., Fahn, S., Freed, C. R., & Parkinson Study Group. (2008). Placebo response in Parkinson’s disease: comparisons among 11 trials covering medical and surgical interventions. Movement Disorders, 23(5), 690–699. https://doi.org/10.1002/mds.21894
Hackney, M. E., & Earhart, G. M. (2009). Effects of dance on movement control in Parkinson’s disease: a comparison of Argentine tango and American ballroom. Journal of Rehabilitation Medicine, 41(6), 475–481. https://doi.org/10.2340/16501977-0362
Hamilton, C., Hamilton, D., Nicklason, F., & Mitrofanis, J. (2019). Exploring the use of transcranial photobiomodulation in Parkinson’s disease patients. Photobiomodulation, Photomedicine, and Laser Surgery, 37(10), 615–622. https://doi.org/10.1089/photob.2019.4673
Hauser, R. A., Lyons, K. E., McClain, T., Carter, S., & Perlmutter, D. (2009). Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Movement Disorders, 24(7), 979–983. https://doi.org/10.1002/mds.22401
Ibrahim, A., Ali, R. A. R., Manaf, M. R. A., Ahmad, N., Tajurruddin, M. F. W., & Din, N. (2020). Multi-strain probiotics are effective treatment approach for Parkinson’s disease with constipation as cardinal presenting symptom. Asian Pacific Journal of Tropical Medicine, 13, 378–383. https://doi.org/10.4103/1995-7645.285893
Katzenschlager, R., Evans, A., Manson, A., Patsalos, P. N., Ratnaraj, N., Watt, H., & Lees, A. J. (2004). Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. Journal of Neurology, Neurosurgery & Psychiatry, 75(12), 1672–1677. https://doi.org/10.1136/jnnp.2003.028761
Kuo, H. C., Lu, C. C., Shen, C. H., Tung, S. Y., Hsieh, M. C., Lee, K. C., & Teng, C. C. (2016). Hericium erinaceus mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade. International Journal of Molecular Sciences, 17(6), 807. https://doi.org/10.3390/ijms17060807
Lampariello, L. R., Cortelazzo, A., Guerranti, R., Sticozzi, C., & Valacchi, G. (2012). The magic velvet bean of Mucuna pruriens. Journal of Traditional and Complementary Medicine, 2(4), 331–339. https://doi.org/10.1016/s2225-4110(16)30119-5
Lee, M. S., Shin, B. C., Kong, J. C., & Ernst, E. (2008). Effectiveness of acupuncture for Parkinson’s disease: a systematic review. Movement Disorders, 23(11), 1505–1515. https://doi.org/10.1002/mds.22108
Lefaucheur, J. P., Aleman, A., Baeken, C., Benninger, D. H., Brunelin, J., Di Lazzaro, V., & Garcia-Larrea, L. (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update. Clinical Neurophysiology, 131(2), 474–528. https://doi.org/10.1016/j.clinph.2019.11.002
Levin, J., Maaβ, S., Schuberth, M., Respondek, G., Paul, F., Mansmann, U., & Höglinger, G. U. (2019). The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation approach. Journal of Neural Transmission, 126(7), 849–856. https://doi.org/10.1007/s00702-019-01999-8
Li, F., Harmer, P., Fitzgerald, K., Eckstrom, E., Stock, R., Galver, J., & Batya, S. S. (2012). Tai chi and postural stability in patients with Parkinson’s disease. New England Journal of Medicine, 366(6), 511–519. https://doi.org/10.1056/NEJMoa1107911
Liu, F. T., Cao, J. S., Huang, X. L., Fan, Y. Y., & Wu, J. J. (2024). The effects of Tai Chi on balance function, motor function, and quality of life in patients with Parkinson’s disease: a meta-analysis. Frontiers in Aging Neuroscience, 16, 1342978. https://doi.org/10.3389/fnagi.2024.1342978
Luo, X., Ou, R., Dutta, R., Tian, Y., Xiong, H., & Shang, H. (2021). Association between serum vitamin D levels and Parkinson’s disease: a systematic review and meta-analysis. Frontiers in Neurology, 9, 909. https://doi.org/10.3389/fneur.2018.00909
Mandel, S. A., Amit, T., Kalfon, L., Reznichenko, L., & Youdim, M. B. H. (2006). Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins. Journal of Nutrition, 138(8), 1578S–1583S. https://doi.org/10.1093/jn/138.8.1578S
Manyam, B. V. (1990). Paralysis agitans and levodopa in “Ayurveda”: ancient Indian medical treatise. Movement Disorders, 5(1), 47–48. https://doi.org/10.1002/mds.870050112
Mattson, M. P., Moehl, K., Ghena, N., Schmaedick, M., & Cheng, A. (2018). Intermittent metabolic switching, neuroplasticity and brain health. Nature Reviews Neuroscience, 19(2), 63–80. https://doi.org/10.1038/nrn.2017.156
McLean, G., Lawrence, M., Simpson, R., & Mercer, S. W. (2017). Mindfulness-based stress reduction in Parkinson’s disease: a systematic review. BMC Neurology, 17(1), 92. https://doi.org/10.1186/s12883-017-0876-4
Metcalfe-Roach, A., Yu, A. C., Golz, E., Cirstea, M., Sundvick, K., Foulger, A., & Bhatt, D. L. (2021). MIND and Mediterranean diets associated with later onset of Parkinson’s disease. Movement Disorders, 36(4), 977–984. https://doi.org/10.1002/mds.28464
Mischley, L. K., Lau, R. C., & Bennett, R. D. (2017). Role of diet and nutritional supplements in Parkinson’s disease progression. Oxidative Medicine and Cellular Longevity, 6405278. https://doi.org/10.1155/2017/6405278
Monti, D. A., Zabrecky, G., Kremens, D., Liang, T. W., Wintering, N. A., Cai, J., & Newberg, A. B. (2016). N-Acetyl Cysteine may support dopamine neurons in Parkinson’s disease: preliminary clinical and cell line data. PLoS ONE, 11(6), e0157602. https://doi.org/10.1371/journal.pone.0157602
Mori, K., Inatomi, S., Ouchi, K., Azumi, Y., & Tuchida, T. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research, 23(3), 367–372. https://doi.org/10.1002/ptr.2634
Müller, T., Renger, K., & Kuhn, W. (2013). Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Clinical Neuropharmacology, 27(1), 19–23. https://doi.org/10.1097/wnf.0000000000000010
Nagashayana, N., Sankarankutty, P., Nampoothiri, M. R., Mohan, P. K., & Mohanakumar, K. P. (2000). Association of L-DOPA with recovery following Ayurveda medication in Parkinson’s disease. Journal of the Neurological Sciences, 176(2), 124–127. https://doi.org/10.1016/s0022-510x(00)00329-x
Oertel, W. H., Berardelli, A., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., & Neukirchen, M. (2022). NIC-PD: nicotine in Parkinson’s disease — a double-blind, placebo-controlled trial. The Lancet Neurology, 21(10), 901–909. https://doi.org/10.1016/S1474-4422(22)00289-6
Pacchetti, C., Mancini, F., Aglieri, R., Fundaro, C., Martignoni, E., & Nappi, G. (2000). Active music therapy in Parkinson’s disease: an integrative method for motor and emotional rehabilitation. Psychosomatic Medicine, 62(3), 386–393. https://doi.org/10.1097/00006842-200005000-00012
Parkinson Study Group QE3 Investigators. (2014). A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurology, 71(5), 543–552. https://doi.org/10.1001/jamaneurol.2014.131
Peball, M., Krismer, F., Knaus, H. G., Djamshidian, A., Werkmann, M., Ellmerer, P., & Wenning, G. K. (2020). Non-motor symptoms in Parkinson’s disease are reduced by nabilone. Annals of Neurology, 88(4), 712–722. https://doi.org/10.1002/ana.25683
Phillips, M. C. L., Murtagh, D. K. J., Gilbertson, L. J., Asztely, F. J. S., & Lynch, C. D. P. (2018). Low-fat versus ketogenic diet in Parkinson’s disease: a pilot randomized controlled trial. Movement Disorders, 33(8), 1306–1314. https://doi.org/10.1002/mds.27390
Pickut, B. A., Van Hecke, W., Kerckhofs, E., Mariën, P., Vanneste, S., Cras, P., & Parizel, P. M. (2015). Mindfulness based intervention in Parkinson’s disease leads to structural brain changes on MRI. Clinical Neurology and Neurosurgery, 132, 86–90. https://doi.org/10.1016/j.clineuro.2015.02.001
Pincus, J. H., & Barry, K. M. (1987). Influence of dietary protein on motor fluctuations in Parkinson’s disease. Archives of Neurology, 44(3), 270–272. https://doi.org/10.1001/archneur.1987.00520150022009
Quik, M., Bordia, T., & O’Leary, K. (2012). Nicotinic receptors as CNS targets for Parkinson’s disease. Biochemical Pharmacology, 74(8), 1224–1234. https://doi.org/10.1016/j.bcp.2007.06.056
Rajendran, P. R., Thompson, R. E., & Reich, S. G. (2001). The use of alternative therapies by patients with Parkinson’s disease. Neurology, 57(5), 790–794. https://doi.org/10.1212/wnl.57.5.790
RajaSankar, S., Manivasagam, T., Sankar, V., Prakash, S., Muthusamy, R., Krishnamurti, A., & Suresh Babu, S. (2009). Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson’s disease model mouse. Journal of Ethnopharmacology, 125(3), 369–373. https://doi.org/10.1016/j.jep.2009.08.002
Salehpour, F., Mahmoudi, J., Kamari, F., Sadigh-Eteghad, S., Rasta, S. H., & Hamblin, M. R. (2018). Brain photobiomodulation therapy: a narrative review. Molecular Neurobiology, 55(8), 6601–6636. https://doi.org/10.1007/s12035-017-0852-4
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., & Mazmanian, S. K. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell, 167(6), 1469–1480. https://doi.org/10.1016/j.cell.2016.11.018
Saper, R. B., Kales, S. N., Paquin, J., Burns, M. J., Eisenberg, D. M., Davis, R. B., & Phillips, R. S. (2004). Heavy metal content of Ayurvedic herbal medicine products. JAMA, 292(23), 2868–2873. https://doi.org/10.1001/jama.292.23.2868
Scheperjans, F., Aho, V., Pereira, P. A., Koskinen, K., Paulin, L., Pekkonen, E., & Auvinen, P. (2015). Gut microbiota are related to Parkinson’s disease and clinical phenotype. Movement Disorders, 30(3), 350–358. https://doi.org/10.1002/mds.26069
Sechi, G., Deledda, M. G., Bua, G., Satta, W. M., Deiana, G. A., Pes, G. M., & Rosati, G. (1996). Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 20(7), 1159–1170. https://doi.org/10.1016/s0278-5846(96)00103-0
Sharp, K., & Hewitt, J. (2014). Dance as an intervention for people with Parkinson’s disease: a systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 47, 445–456. https://doi.org/10.1016/j.neubiorev.2014.09.009
Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., & Srinivas, P. S. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica, 64(4), 353–356. https://doi.org/10.1055/s-2006-957450
Suzuki, M., Yoshioka, M., Hashimoto, M., Murakami, M., Noya, M., Takahashi, D., & Ohsaki, Y. (2013). Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. American Journal of Clinical Nutrition, 97(5), 1004–1013. https://doi.org/10.3945/ajcn.112.051664
Tamtaji, O. R., Taghizadeh, M., Daneshvar Kakhaki, R., Kouchaki, E., Bahmani, F., Borzabadi, S., & Asemi, Z. (2019). Clinical and metabolic response to probiotic administration in people with Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. Clinical Nutrition, 38(3), 1031–1035. https://doi.org/10.1016/j.clnu.2018.05.018
Thaut, M. H., McIntosh, G. C., Rice, R. R., Miller, R. A., Rathbun, J., & Brault, J. M. (1996). Rhythmic auditory stimulation in gait training for Parkinson’s disease patients. Movement Disorders, 11(2), 193–200. https://doi.org/10.1002/mds.870110213
The Parkinson Study Group. (1993). Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. New England Journal of Medicine, 328(3), 176–183. https://doi.org/10.1056/NEJM199301213280305
Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D. C., Yan, S. D., & Przedborski, S. (2003). D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. Journal of Clinical Investigation, 112(6), 892–901. https://doi.org/10.1172/JCI18797
Tillerson, J. L., Caudle, W. M., Reveron, M. E., & Miller, G. W. (2003). Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson’s disease. Neuroscience, 119(3), 899–911. https://doi.org/10.1016/s0306-4522(03)00096-4
Yoritaka, A., Takanashi, M., Hirayama, M., Nakahara, T., Ohta, S., & Hattori, N. (2013). Pilot study of H₂ therapy in Parkinson’s disease: a randomized double-blind placebo-controlled trial. Movement Disorders, 28(6), 836–839. https://doi.org/10.1002/mds.25375
Zigmond, M. J., Cameron, J. L., Leak, R. K., Bhatt, D. L., & Joseph, J. A. (2012). Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency. Parkinsonism & Related Disorders, 15(Suppl 3), S42–S45. https://doi.org/10.1016/S1353-8020(09)70789-0
Chapter 8: Natural & Unconventional Treatments | Parkinson’s Disease Academic Reference | adrianmicu.ro | Last updated: February 2025 | Total treatments reviewed: 42 | References: 55+ peer-reviewed sources | All content is original and intended for educational purposes only. This page does not constitute medical advice. Patients should consult their neurologist before initiating any complementary therapy.
Chapter Navigation: ← Chapter 7: The Genetics of Parkinson’s Disease | Chapter 9: Pharmacological Treatment →